Ultragenyx Pharmaceutical Inc.RARE
Price (close)
$14.77
Market cap
$1.5B
P/E
—
Revenue (TTM)
$717.2M
Net income
-$586.0M
Dividend yield
—
1-year total return
-46.9%
Net margin
-81.7%
Revenue growth
17.5%
Debt / equity
—
What Ultragenyx Pharmaceutical Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $271.0M | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| Net income | -$186.6M | -$454.0M | -$707.4M | -$607.0M | -$569.0M | -$575.0M |
| Free cash flow | -$176.1M | -$411.8M | -$496.6M | -$519.0M | -$421.0M | -$472.0M |
More on RARE.
- Ultragenyx Pharmaceutical Inc. summary
- Ultragenyx Pharmaceutical Inc. financial statements
- Ultragenyx Pharmaceutical Inc. key metrics
- Ultragenyx Pharmaceutical Inc. health scores and style box
- Ultragenyx Pharmaceutical Inc. earnings
- Ultragenyx Pharmaceutical Inc. dividends
- Ultragenyx Pharmaceutical Inc. valuation
- Ultragenyx Pharmaceutical Inc. ownership and insiders
- Ultragenyx Pharmaceutical Inc. peers
Figures from Ultragenyx Pharmaceutical Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.